This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

This study has been terminated.
(The study was stopped due to slow rate of recruitment.)
Stanford University
Information provided by (Responsible Party):
VentiRx Pharmaceuticals Inc. Identifier:
First received: February 1, 2011
Last updated: September 29, 2014
Last verified: September 2014
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Condition Intervention Phase
Low Grade B Cell Lymphoma Drug: VTX-2337 plus radiotherapy Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

Resource links provided by NLM:

Further study details as provided by VentiRx Pharmaceuticals Inc.:

Primary Outcome Measures:
  • Number of Participants Whose Tumors Responded to Treatment With Intratumoral Injection of VTX-2337 in Combination With Low-Dose Local Radiation. [ Time Frame: Tumor assessment conducted at 12 weeks and every 3-6 months thereafter ]
    Tumor response was assessed via CT scans of the chest, abdomen, pelvis or other medically appropriate imaging modality to evaluate all areas of disease. Cheson Criteria were used for calculation of response.

Secondary Outcome Measures:
  • Assess the Safety and Feasibility of the Combination Regimen. [ Time Frame: Safety assessed throughout study period. ]

Enrollment: 2
Study Start Date: July 2011
Study Completion Date: October 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
VTX-2337 plus radiation Drug: VTX-2337 plus radiotherapy
Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Major Inclusion Criteria:

  • low grade B cell lymphoma
  • 1 or more sites of disease appropriate for intratumoral injection
  • measurable disease other than the injection site
  • Performance Status of 1 or better
  • Adequate bone marrow, renal and hepatic function
  • No active autoimmune disease or systemic immunosuppressive drugs
  • Life expectancy > 4 months

Exclusion Criteria:

  • Known HIV
  • Known brain metastases
  • Malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma OK)
  • Anticoagulation therapy other than 325mg QD ASA
  • Significant cardiovascular disease
  • Pregnant or nursing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01289210

United States, California
Stanford Cancer Center
Stanford, California, United States, 94305
Sponsors and Collaborators
VentiRx Pharmaceuticals Inc.
Stanford University
Principal Investigator: Ronald Levy, MD Stanford University
  More Information

Responsible Party: VentiRx Pharmaceuticals Inc. Identifier: NCT01289210     History of Changes
Obsolete Identifiers: NCT01396018
Other Study ID Numbers: VRXP-A104
Study First Received: February 1, 2011
Results First Received: May 28, 2014
Last Updated: September 29, 2014

Keywords provided by VentiRx Pharmaceuticals Inc.:
B cell

Additional relevant MeSH terms:
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin processed this record on September 20, 2017